CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- 4 Grant or award CHIEF EXECUTIVE OFFICER acquired 90,500 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Option exercise 10% owner acquired 1,700 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4/A Insider Changes in Ownership
- 4/A Insider Changes in Ownership
- 4 Grant or award Director acquired 5,250 shares (grant or award)
- 4 Grant or award Director acquired 5,250 shares (grant or award)
- 4 Grant or award Director acquired 5,250 shares (grant or award)
- 4 Grant or award Director acquired 5,250 shares (grant or award)
- 4 Grant or award Director acquired 5,250 shares (grant or award)
- 4 Grant or award Director acquired 5,250 shares (grant or award)
- 4 Grant or award Director acquired 5,250 shares (grant or award)
- 4 Grant or award Director acquired 5,250 shares (grant or award)
- 4 Open-market buy 10% owner bought 934,258 shares at an average $10.13 ($9,464,512)
- 3 Insider Initial Statement of Ownership
- 4 Option exercise CHIEF EXECUTIVE OFFICER acquired 49,367 shares (option exercise)
- 4 Grant or award Chief Medical Officer acquired 44,000 shares (grant or award)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 44,000 shares (grant or award)
Page 3 of 11 · 206 filings